This article was originally published in The Tan Sheet
Worldwide sales of nutritional products during the fourth quarter were fueled by the performance of the international division, which posted sales growth of 26.2% to $571 mil., Abbott Labs says in Jan. 23 release. International growth was driven by a 6.6% favorable impact from exchange, "with continued strong growth in Latin American and Asian markets," firm says. Total sales of the division increased 11.2% to $1.19 bil. Revenues for U.S. nutritional products were flat at $616 mil., however, excluding the impact of a co-promotion agreement for Rx drug Synagis, U.S. sales of the unit advanced 11%, Abbott notes. For the year, Abbott's international nutritional products division had sales growth of 18.4% to $2.04 bil., boosting net sales for nutritionals 1.7% to $4.39 bil. U.S. nutritional revenues fell 9.4% to $2.35 bil., reflecting the impact of Synagis...
Sign in to continue reading.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: